Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia

European Journal of Haematology

Volumn 85, Issue 1, 2010, Pages 86-87

  Tefferi, Ayalew ^a   Levitt, Ralph ^b   Lasho, Terra L ^a   Knudson, Ryan A ^a   Ketterling, Rhett P ^a  

^a MAYO CLINIC   (United States)

^b MeritCare Roger Maris Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HYDROXYUREA; IMATINIB; JANUS KINASE 2;

AGED; ANAMNESIS; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; LABORATORY TEST; LETTER; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN VARIANT;

AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; GENES, ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION, MISSENSE; PIPERAZINES; POLYCYTHEMIA VERA; PYRIMIDINES; TIME FACTORS;

EID: 77953865246     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01458.x     Document Type: Letter

References (22)

1. Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 2010 91 : 136 139.
2. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina, M, Bosi, A, Francesco, L. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007 8 : 864 866.
3. Pingali SR, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 2009 9 : E25 9.
4. Mirza I, Frantz C, Clarke G, Voth AJ, Turner R. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 2007 131 : 1719 1724.
5. Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, Büsche G, Kreipe H. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 2008 22 : 1059 1062.
6. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, French M. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008 32 : 1608 1610.
7. Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007 8 : 658 660.
8. Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 2009 33 : e212 3.
9. Gattenlohner S, Volker HU, Etschmann B, Einsele H, Muller-Hermelink HK. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol 2009 84 : 306 307.
10. Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 2008 88 : 243 245.
11. Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Laï JL, Rose C, Preudhomme C. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008 22 : 1454 1455.
12. Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, Chung IJ, Ryang DW, Kim HJ. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res 2008 32 : 993 995.
13. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007 21 : 1103 1104.
14. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008 22 : 14 22.
15. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009 361 : 1872 1885.
16. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010 24 : 105 109.
17. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, Tefferi A. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010 24 : 110 114.
18. Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009 114 : 3018 3023.
19. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009 41 : 450 454.
20. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010 115 : 2003 2007.
21. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2009 113 : 2022 2027.
22. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008 22 : 3 13.